Methods for performing genome editing in microalgae

The nucleic acid construct with a promoter, gRNA, and terminator sequence enhances genome editing efficiency in Nannochloropsis microalgae, allowing for precise genetic modifications and strain development.

JP7587838B2Active Publication Date: 2024-11-21HIROSHIMA UNIVERSITY
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
JP2021132753
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-08-27
Filing Date
2021-08-17
Publication Date
2024-11-21
Estimated Expiration
2041-08-17

AI Technical Summary

Technical Problem

Existing genome editing technologies are inefficient for Nannochloropsis microalgae, limiting the ability to precisely modify their genome and create strains with new properties.

Method used

A nucleic acid construct comprising a promoter sequence that recruits Type III RNA polymerase of Nannochloropsis microalgae, a guide RNA (gRNA) operably linked to the promoter sequence, and a terminator sequence that terminates transcription, optimized for high-efficiency genome editing using the Crispr/Cas9 system.

Benefits of technology

Enables precise and efficient genome editing in Nannochloropsis microalgae, facilitating genetic manipulation and the creation of strains with desired traits.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007587838000024
    Figure 0007587838000024
  • Figure 0007587838000025
    Figure 0007587838000025
  • Figure 0007587838000026
    Figure 0007587838000026
Patent Text Reader

Abstract

To provide genome editing in microalgae.SOLUTION: In one aspect, the disclosure provides a nucleic acid construct for conducting genome editing in Nannochloropsis microalgae, or a method for conducting genome editing using the same. The disclosure also provides Nannochloropsis microalgae comprising the nucleic acid construct. Further the disclosure provides a nucleic acid or a method for constructing the nucleic acid construct. In one embodiment, the disclosure can provide a plasmid that enables the expression of a single-stranded guide RNA in Nannochloropsis microalgae.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present disclosure provides a nucleic acid construct for performing genome editing in Nannochloropsis microalgae, or a method for performing genome editing using the same.The present disclosure also provides a Nannochloropsis microalgae comprising the nucleic acid construct.Furthermore, the present disclosure provides a nucleic acid for constructing the nucleic acid construct, or a method for constructing the same. [Background technology]

[0002] Nannochloropsis microalgae have the property of accumulating oils and fats, and are expected to be used as a means of producing biofuel and as feed for fish and the like. In applying and utilizing Nannochloropsis species with such properties, a technique for artificially modifying their genome sequence is useful. One of the techniques for artificially modifying the genome of an organism is genome editing technology. The present invention can be used to precisely modify the genome of Nannochloropsis species with high efficiency using genome editing technology, and to create varieties (strains) of Nannochloropsis species with new properties.

[0003] Methods such as Crispr / Cas9 and TALEN can be used to perform genome editing in eukaryotes (e.g., International Publication No. 2014 / 199358). In the Crispr / Cas9 method, two elements, the Cas9 protein and gRNA, are introduced into the target cells. Once an experimental system has been successfully constructed, Crispr / Cas9 can perform genome editing on almost all genes contained in the genome of an organism by simply modifying a portion (approximately 20 bp) of the gRNA base sequence. Therefore, it is desirable to establish a Crispr / Cas9 method that is useful in target organisms. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] International Publication No. 2014 / 199358 Summary of the Invention [Means for solving the problem]

[0005] The present inventors have found a structure of a nucleic acid construct that can perform genome editing in Nannochloropsis microalgae with high efficiency.Based on this finding, the present disclosure also provides a nucleic acid construct for performing genome editing in Nannochloropsis microalgae, a method for performing genome editing using the same, and a Nannochloropsis microalgae that includes the nucleic acid construct.Furthermore, the present disclosure provides a nucleic acid for constructing the nucleic acid construct or a method for constructing the same.

[0006] Thus, the present invention provides the following: (Item 1) A promoter sequence that recruits Type III RNA polymerase from Nannochloropsis microalgae. a sequence encoding a guide RNA (gRNA), operably linked to the promoter sequence; and A terminator sequence that terminates transcription by the Type III RNA polymerase of Nannochloropsis microalgae, operably linked to the sequence encoding the gRNA; A nucleic acid construct comprising: (Item 2) 2. The nucleic acid construct according to item 1, wherein the promoter sequence is a promoter sequence of the U6 RNA gene of Nannochloropsis microalgae. (Item 3) The promoter sequence is the sequence of SEQ ID NO:1 (CCAAATGTCTTTGACGGTCGTCACGGTTTTGCGTCGTAAAACCTACGCAAGGAAAATTACCATCATCGACCCGACACAAACAAGCGGTCCTTAGAAATCAGGACCTTTTATTTTTTAAGAAGGGAGTGAATGGGTAACAT TTCGTGGTGAGACTTCAACGAAAGTTTGGAGAAAAATTCCACATGTTGTACGCTCCCGGAAAAGAGAAGGAATATAAGGGCGTCACGAGTCATGACTTTCTAAACAGCAAGGTTCGCGTGAAACTCGTTTACGGGAAACC) The nucleic acid construct according to item 1 or 2, comprising a sequence having at least 85% identity with (item 4). 4. The nucleic acid construct according to any one of items 1 to 3, wherein the terminator sequence comprises at least 4 consecutive thymidine bases. (Item 5) 5. The nucleic acid construct according to any one of items 1 to 4, wherein the terminator sequence is a terminator sequence of the U6 RNA gene of Nannochloropsis microalgae. (Item 6) The terminator sequence is the sequence of SEQ ID NO:2 (TTTTTTTTCTTTTGATCAAATTACATTCTGATTCTTAGATACTTCACATGTTGATACTCCAC) 6. The nucleic acid construct according to any one of items 1 to 5, comprising a sequence having at least 85% identity with (Item 7) 7. The nucleic acid construct according to any one of items 1 to 6, wherein the sequence encoding the gRNA comprises a protospacer adjacent motif (PAM). (Item 8) The sequence encoding the gRNA is the sequence of SEQ ID NO: 3 (GTTTAAGAGCTATGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC) 8. The nucleic acid construct according to any one of items 1 to 7, comprising a sequence having at least 85% identity with (Item 9) 9. The nucleic acid construct according to any one of items 1 to 8, wherein the sequence encoding the gRNA comprises a sequence of 15 to 25 bases in length from a sequence encoding a target gene. (Item 10) 10. The nucleic acid construct according to any one of items 1 to 9, wherein the sequence encoding the gRNA comprises a PAM and a 15 to 25 base sequence located on the 5' side of the PAM in the sequence encoding the target gene. (Item 11) 11. The nucleic acid construct according to item 9 or 10, wherein the target gene is green fluorescent protein (GFP). (Item 12) 12. The nucleic acid construct according to any one of items 1 to 11, wherein the gRNA is a single-stranded guide RNA. (Item 13) 13. The nucleic acid construct of any one of items 1 to 12, further comprising a sequence encoding a Cas9 protein. (Item 14) 16. The nucleic acid construct according to any one of items 1 to 15, further comprising a sequence encoding a drug selection marker. (Item 15) 15. The nucleic acid construct according to any one of items 1 to 14, wherein the Nannochloropsis microalgae is N. oceanica. (Item 16) 16. The nucleic acid construct according to any one of items 1 to 15, which is a plasmid. (Item 17) 17. A Nannochloropsis microalga comprising the nucleic acid construct according to any one of items 1 to 16. (Item 18) A kit for preparing a nucleic acid construct for performing genome editing in Nannochloropsis microalgae, A nucleic acid comprising a promoter sequence that recruits Type III RNA polymerase from Nannochloropsis microalgae; A nucleic acid containing a terminator sequence that terminates transcription by Type III RNA polymerase of Nannochloropsis microalgae. Including the kit. (Item 19) 1. A method for performing genome editing in Nannochloropsis microalgae, comprising: A step of introducing the nucleic acid construct according to any one of items 1 to 16 or the nucleic acid in the kit according to item 18 into Nannochloropsis microalgae. The method includes:

[0007] It is contemplated that one or more of the above features may be provided in combinations other than those specifically described. Still further embodiments and advantages of the present invention will be recognized by those skilled in the art upon reading and understanding the following detailed description, if necessary. Effect of the Invention

[0008] The present disclosure may enable highly efficient genome editing in Nannochloropsis microalgae, thereby providing easy genetic manipulation of Nannochloropsis microalgae. [Brief description of the drawings]

[0009] [Figure 1] The results of electrophoresis confirming the production of the 1006 bp α-tubulin promoter are shown. [Diagram 2] A schematic diagram of the construction of pNAN0006 is shown. [Diagram 3] A) Schematic diagram of the structure of pNAN0006. B) SDS-PAGE of proteins extracted from wild-type strain (1) and pNAN0006 transformed strains (2, 3, 4). C) Western blot with anti-Cas9 antibody. [Figure 4] A schematic diagram of the construction of pNAN1001, pNAN1002, and pNAN1003 is shown. [Diagram 5]The U6RNA-like gene and its surrounding sequences obtained from N. oceanica NIES 2145 strain are shown. The bold (black) part is presumed to code for the promoter, the sequence between (red) for the U6RNA, and the italics (green) for the terminator. The underlined parts indicate the sequences used for the primers. The 3' and 5' parts (light blue) shown separately represent part of the sequence of the vector used for cloning. [Figure 6] A) Schematic diagram of the structure of pNAN1001, pNAN1002, and pNAN1003. B) Schematic diagram of the structure of the expression cassette of pNAN1001, pNAN1002, and pNAN1003. [Figure 7] A) Electrophoresis of samples of RNA extracted from pNAN1001 transformants, pNAN1002 transformants, pNAN1003 transformants, and wild-type strain (WT) treated with (+) or without (-) reverse transcriptase (110 bp gRNA cDNA). B) Electrophoresis of samples of RNA extracted from pNAN1001 transformants, pNAN1002 transformants, pNAN1003 transformants, and wild-type strain (WT) treated with (+) or without (-) reverse transcriptase (230 bp β-tubulin mRNA cDNA). [Figure 8] A schematic diagram of the structure of pNAN0005 is shown. [Figure 9] A) Fluorescent stereomicroscope images of colonies formed on an agar medium of a pNAN0005 transformed strain. B) to D) Fluorescent stereomicroscope images of colonies formed from a strain further transformed with pNAN1002. [Figure 10] This shows an analysis of the GFP gene in cells in which genome editing was performed by transformation with pNAN1002. After PCR amplification of the GFP gene (a 201bp or 756bp fragment appears), the fragment was digested with AluI. 1 to 10 show the experimental results of independent strains. In strains in which genome editing has occurred, a 105bp band appears. Genome editing has occurred in 1, 2, 5, 6, and 7. [Figure 11] 1 shows changes in the partial nucleotide sequence of the GFP gene resulting from transformation of pNAN1002. [Figure 12]1 shows a schematic diagram of the construction of pNAN1006 based on pNAN1002. [Figure 13] The results of electrophoresis of PCR amplified products of a portion of the CA2 gene obtained from each colony with or without treatment with EcoRV are shown. 1: Wild-type strain, not treated with EcoRV. 2: Wild-type strain, treated with EcoRV. 3 to 10: Zeocin-resistant colonies generated after transformation with pNAN1006, treated with EcoRV, respectively. The 516 bp band indicates the occurrence of genome editing. [Figure 14] Shown are fluorescence micrographs (A-C) of colonies of the NIES-2146, NIES-2587, and NIES-2588 strains into which pNAN0005 had been introduced, as well as photographs of colonies of each strain into which pNAN1002 had been introduced and genome editing had been performed (D, E), and photographs of colonies that had become entirely red after single colony isolation from colonies that contained red areas (F-H). [Figure 15] This shows the change in the base sequence at the target site of the GFP gene in the colony strains that began to show red fluorescence. The top is the sequence of the wild-type GFP gene (16-80). 1 and 2 are the base sequences of the GFP gene of the strain derived from NIES-2146, 3 and 4 are the strain derived from NIES-2587, and 5 and 6 are the base sequences of the GFP gene of the strain derived from NIES-2588. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The present disclosure will be described below while showing the best mode. Throughout this specification, the expression of the singular form should be understood to include the concept of the plural form, unless otherwise specified. Therefore, the singular article (for example, in the case of English, "a", "an", "the", etc.) should be understood to include the concept of the plural form, unless otherwise specified. In addition, it should be understood that the terms used in this specification are used in the sense commonly used in the field, unless otherwise specified. Therefore, unless otherwise defined, all technical terms and scientific and technical terms used in this specification have the same meaning as commonly understood by those skilled in the art to which this disclosure belongs. In case of conflict, the present specification (including definitions) will take precedence.

[0011] The following provides definitions of terms particularly used in this specification and / or explains basic technical content as appropriate.

[0012] As used herein, "genome editing" refers to the artificial modification of genes in cells. The genes modified by genome editing may be endogenous genes of a species or may be present on a nucleic acid construct (e.g., a plasmid) exogenously introduced into the organism.

[0013] As used herein, "protein", "polypeptide" and "peptide" are used interchangeably to refer to a polymer of amino acids of any length. The polymer may be linear, branched or cyclic. The amino acids may be natural, non-natural or modified. The term also encompasses naturally or artificially modified polymers. Such modifications include, for example, disulfide bond formation, glycosylation, lipidation, acetylation, phosphorylation or any other manipulation or modification (e.g., conjugation with a labeling moiety).

[0014] As used herein, "polynucleotide" and "nucleic acid" are used interchangeably to refer to a polymer of nucleotides of any length. Examples of nucleic acids include DNA, RNA, cDNA, mRNA, rRNA, tRNA, microRNA (miRNA), and lncRNA. This term also includes "polynucleotide derivatives." "Polynucleotide derivatives" refers to polynucleotides that contain nucleotide derivatives or have unusual internucleotide bonds. The term "nucleotide derivative" refers to a nucleotide having a structure different from that of normal nucleotides used in natural DNA or RNA, such as locked nucleic acid (LNA), ethylene nucleic acid such as 2'-O,4'-C-ethylene bridged nucleic acid (ENA), other bridged nucleic acid (BNA), hexitol nucleic acid (HNA), amide-bridged nucleic acid (AmNA), morpholino nucleic acid, tricyclo-DNA (tcDNA), polyether nucleic acid (see, for example, U.S. Pat. No. 5,908,845), cyclohexene nucleic acid (CeNA), etc. Examples of internucleotide bonds that are different from normal ones include interoligonucleotide bonds in which the phosphodiester bond is converted to a phosphorothioate bond, interoligonucleotide bonds in which the phosphodiester bond is converted to an N3'-P5' phosphoramidate bond, and interoligonucleotide bonds in which the ribose and phosphodiester bond are converted to a peptide nucleic acid bond.

[0015] Unless otherwise indicated, a particular nucleic acid sequence is also intended to encompass the sequence explicitly indicated, as well as conservatively modified variants thereof (e.g., degenerate codon substitutions) and complementary sequences. Specifically, degenerate codon substitutions can be achieved by creating sequences in which the third position of one or more selected (or all) codons is substituted with mixed-base and / or deoxyinosine residues.

[0016] As used herein, the term "nucleic acid construct" refers to an artificially produced nucleic acid molecule. Any known method, such as a method using an enzyme (such as a restriction enzyme), chemical synthesis, or a method using an organism (such as E. coli), can be used to produce a nucleic acid construct. The nucleic acid construct may be RNA or DNA, may contain modified nucleotides, and is typically a plasmid.

[0017] As used herein, the term "gene" refers to a nucleic acid portion that performs a certain biological function. The biological functions include encoding a polypeptide or protein, encoding a protein-noncoding functional RNA (guide RNA, rRNA, tRNA, microRNA (miRNA), lncRNA, etc.), controlling the production of a polypeptide, protein, or protein-noncoding functional RNA, specifically binding to a specific protein, and controlling the cleavage or replication of a nucleic acid. Therefore, in addition to the nucleic acid portion that encodes a protein or protein-noncoding functional RNA, genes in this specification also include transcription-translation regulatory sequences such as promoters, terminators, enhancers, silencers, and replication origins. As used herein, a "gene product" may refer to a polypeptide, protein, or protein-noncoding functional RNA encoded by a gene.

[0018] As used herein, "operably linked" refers to a state in which the expression (operation) of a desired sequence is placed under the control of a certain transcriptional / translational regulatory sequence (e.g., promoter, enhancer, etc.) or translational regulatory sequence. In order for a promoter to be operably linked to a gene, the promoter is usually placed immediately upstream of the gene, but is not necessarily placed adjacent to the gene.

[0019] As used herein, "transcriptional / translational regulatory sequences" collectively refer to promoters, polyadenylation signals, transcriptional termination sequences, upstream regulatory domains, replication origins, enhancers, and the like, which cooperate to allow the replication, transcription, and translation of coding sequences in cells. Not all of these transcriptional / translational regulatory sequences need to be present, as long as the replication, transcription, and translation of the selected coding sequence is possible in a suitable host cell. Those skilled in the art can deduce regions containing regulatory nucleic acid sequences from published information. Furthermore, those skilled in the art can identify transcriptional / translational regulatory sequences that are applicable to the intended use, for example, in vivo, ex vivo, or in vitro.

[0020] As used herein, "promoter" refers to a segment of a nucleic acid sequence that controls the transcription of an operably linked nucleic acid sequence. A promoter comprises a specific sequence that is sufficient for recognition, binding and transcription initiation by RNA polymerase. A promoter may also comprise a sequence that regulates the recognition, binding or transcription initiation of RNA polymerase.

[0021] As used herein, "enhancer" refers to a segment of a nucleic acid sequence that functions to increase the efficiency of expression of a gene of interest.

[0022] As used herein, the term "silencer" refers to a segment of a nucleic acid sequence that has the function of reducing the expression efficiency of a gene of interest, the opposite of that of an enhancer.

[0023] As used herein, "terminator" refers to a segment of a nucleic acid sequence that is located downstream of a region encoding a protein or functional RNA and is involved in terminating transcription when the nucleic acid is transcribed into RNA.

[0024] As used herein, "origin of replication" refers to a segment of a nucleic acid sequence to which a protein that recognizes that nucleic acid sequence binds, partially unwinding the DNA double helix and initiating replication.

[0025] As used herein, the term "homology" of nucleic acids refers to the degree of identity between two or more nucleic acid sequences, and generally, "homology" refers to a high degree of identity or similarity. Thus, the higher the homology between two nucleic acids, the higher the identity or similarity between those sequences. "Similarity" is a value that takes into account similar bases in addition to identity, and similar bases here refer to cases where a portion of mixed bases (e.g., R=A+G, M=A+C, W=A+T, S=C+G, Y=C+T, K=G+T, H=A+T+C, B=G+T+C, D=G+A+T, V=A+C+G, N=A+C+G+T) match. Whether two types of nucleic acids have homology can be examined by direct comparison of sequences or by hybridization methods under stringent conditions. When two nucleic acid sequences are compared directly, the genes are homologous if there is typically at least 50% identity between the nucleic acid sequences, preferably at least 70% identity, and more preferably at least 80%, 90%, 95%, 96%, 97%, 98% or 99% identity between the nucleic acid sequences.

[0026] Amino acids may be referred to herein by either their commonly known three-letter symbols or the one-letter symbols recommended by the IUPAC-IUB Biochemical Nomenclature Commission. Nucleotides may also be referred to by their commonly accepted one-letter codes. In this specification, the comparison of similarity, identity and homology of amino acid and base sequences is calculated using the sequence analysis tool BLAST with default parameters. Identity searches can be performed, for example, using NCBI's BLAST 2.10.1+ (issued June 18, 2020). The identity value in this specification usually refers to the value when aligned under default conditions using the above BLAST. However, if a higher value is obtained by changing the parameters, the highest value is taken as the identity value. If identity is evaluated in multiple regions, the highest value among them is taken as the identity value. Similarity is a value that takes into account similar amino acids in addition to identity.

[0027] In this specification, unless otherwise specified, a reference to a biological substance (e.g., a protein, a nucleic acid, a gene) is understood to also refer to a variant of the biological substance (e.g., a variant having a modification in the amino acid sequence) that exerts a biological function similar to, but not necessarily to, the biological function of the biological substance. Such variants may include fragments of the original molecule, molecules that are at least 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 98% or 99% identical across the amino acid or nucleic acid sequence of the original biological substance of the same size, or compared to the sequence of the original molecule aligned by computer homology programs known in the art. Variants may include molecules with modified amino acids (e.g., modified by disulfide bond formation, glycosylation, lipidation, acetylation or phosphorylation) or modified nucleotides (e.g., modified by methylation).

[0028] As used herein, "stringent conditions" refers to conditions under which specific hybrids are formed and non-specific hybrids are not formed. For example, stringent conditions include hybridization in 6xSSC (sodium chloride / sodium citrate) at about 45°C, followed by one or more washes in 0.2xSSC, 0.1% SDS at 50-65°C. See Ausubel et al., Current Protocols in Molecular Biology, Wiley Interscience Publishers, (1995).

[0029] As used herein, a "corresponding" amino acid or nucleic acid refers to an amino acid or nucleotide in a polypeptide or polynucleotide molecule that has or is expected to have the same function as a given amino acid or nucleotide in a polypeptide or polynucleotide that is used as a reference for comparison. A corresponding amino acid may be, for example, a specific amino acid that is cysteinized, glutathionylated, forms an SS bond, oxidized (e.g., oxidized methionine side chain), formylated, acetylated, phosphorylated, glycosylated, myristylated, or the like. Such a "corresponding" amino acid or nucleic acid may be a region or domain spanning a certain range. In such a case, it is referred to as a "corresponding" region or domain in this specification.

[0030] As used herein, a "corresponding" gene (e.g., a polynucleotide sequence or molecule) refers to a gene (e.g., a polynucleotide sequence or molecule) in a certain species that has or is predicted to have the same function as a given gene in a species that is used as a reference for comparison, and in the case where there are multiple genes with such function, refers to those that have the same evolutionary origin. For example, a corresponding gene in a certain microalgae species can be found by searching a sequence database of that microalgae species using the gene sequence of the reference microalgae species of the corresponding gene as a query sequence.

[0031] In accordance with the present invention, the term "activity" as used herein refers to the function of a molecule in the broadest sense. Activity generally includes, but is not limited to, the biological, biochemical, physical or chemical functions of a molecule. Activity includes, for example, enzymatic activity, the ability to interact with other molecules, and the ability to activate, promote, stabilize, inhibit, suppress or destabilize the function of other molecules, stability, the ability to localize to a specific subcellular location. Where applicable, the term also relates to the function of a protein complex in the broadest sense.

[0032] As used herein, the term "biological function" refers to a specific function that a gene, a nucleic acid molecule, or a polypeptide related thereto may have in a living body, and includes, but is not limited to, a specific cell surface structure recognition ability, an enzyme activity, and a binding ability to a specific protein. In the present disclosure, for example, a promoter may be recognized in a specific host cell, and the like. As used herein, a biological function may be exerted by "biological activity". As used herein, "biological activity" refers to an activity that a certain factor (e.g., a polynucleotide, a protein, etc.) may have in a living body, and includes an activity that exerts various functions (e.g., a transcription promoting activity), and also includes, for example, an activity that activates or inactivates another molecule by interacting with a certain molecule. For example, when a certain factor is an enzyme, its biological activity includes its enzymatic activity. In another example, when a certain factor is a ligand, its biological activity includes the binding of the ligand to a corresponding receptor. Such biological activity can be measured by a technique well known in the art. Thus, "activity" refers to various measurable indicators that indicate or reveal binding (either directly or indirectly); affect a response (i.e., have a measurable effect in response to some exposure or stimulus), such as a measure of the amount of an upstream or downstream protein or other similar function in a host cell.

[0033] As used herein, "plasmid" refers to circular DNA that exists separately from chromosomes in bacterial cells for construction and amplification, and that, when introduced into algal cells, is either integrated into the chromosome or exists as circular DNA separately from the chromosome. When introduced into algal cells, all or part of the plasmid can be linearized by means of restriction enzyme treatment or PCR amplification, etc., before being used for introduction.

[0034] As used herein, the term "transformation" refers to the introduction of nucleic acid into a host cell. Any method for introducing nucleic acid into a host cell can be used as the transformation method, and includes various well-known techniques such as the use of competent cells, electroporation, a method using a particle gun (gene gun), and calcium phosphate method.

[0035] As used herein, a "purified" substance or biological factor (e.g., a nucleic acid or a protein) refers to a biological factor from which at least a portion of the factors naturally associated with the biological factor have been removed. Thus, the purity of the biological factor in a purified biological factor is usually higher (i.e., concentrated) than the state in which the biological factor normally exists. As used herein, the term "purified" means that preferably at least 75% by weight, more preferably at least 85% by weight, even more preferably at least 95% by weight, and most preferably at least 98% by weight of the same type of biological factor is present. The substance used in the present invention is preferably a "purified" substance.

[0036] In the present specification, the terms "drug", "agent" or "factor" (all of which correspond to the English term agent) are used interchangeably in a broad sense and may refer to any substance or other element (e.g., energy such as light, radioactivity, heat, electricity, etc.) as long as it can achieve the intended purpose. Examples of such substances include, but are not limited to, proteins, polypeptides, oligopeptides, peptides, polynucleotides, oligonucleotides, nucleotides, nucleic acids (e.g., DNA such as cDNA and genomic DNA, and RNA such as mRNA), polysaccharides, oligosaccharides, lipids, small organic molecules (e.g., hormones, ligands, signaling substances, small organic molecules, molecules synthesized by combinatorial chemistry, small molecules that can be used as pharmaceuticals (e.g., small molecule ligands, etc.)), composite molecules thereof, and mixtures thereof.

[0037] As used herein, the term "complex" or "complex molecule" refers to any construct containing two or more parts. For example, when one part is a polypeptide, the other part may be a polypeptide or other substances (e.g., substrates, sugars, lipids, nucleic acids, other carbohydrates, etc.). As used herein, the two or more parts constituting a complex may be bonded by a covalent bond or other bonds (e.g., hydrogen bonds, ionic bonds, hydrophobic interactions, van der Waals forces, etc.).

[0038] As used herein, the term "label" refers to an entity (e.g., a substance, energy, electromagnetic waves, etc.) that distinguishes a target molecule or substance from others. Examples of such labeling methods include the RI (radioisotope) method, the fluorescence method, the biotin method, and the chemiluminescence method. When multiple target proteins or factors or means for capturing them are labeled by the fluorescence method, the labels are used with fluorescent substances that have mutually different maximum fluorescence emission wavelengths. The difference in maximum fluorescence emission wavelength is preferably 10 nm or more. Any label that does not affect the function can be used, but examples of fluorescent substances include Alexa TM Fluor is one example. Alexa TM Fluor is a water-soluble fluorescent dye obtained by modifying coumarin, rhodamine, fluorescein, cyanine, etc., and is a series that corresponds to a wide range of fluorescent wavelengths. It is very stable, bright, and has low pH sensitivity compared to other fluorescent dyes of the corresponding wavelengths. Alexa TM 555 and Alexa TM 633 combinations, Alexa TM 488 and Alexa TM Other examples of fluorescent labels include cyanine dyes (e.g., CyDye 555). TMExamples of such labels include the Cy3 and Cy5 series, rhodamine 6G reagent, N-acetoxy-N2-acetylaminofluorene (AAF), and AAIF (an iodine derivative of AAF). In the present disclosure, such labels can be used to modify the target of interest so that it can be detected by the detection means used. Such modifications are known in the art, and those skilled in the art can carry out such methods appropriately depending on the label and the target of interest.

[0039] As used herein, the term "kit" refers to a unit in which the parts to be provided (e.g., elements constituting a nucleic acid construct, instructions, etc.) are provided, usually divided into two or more compartments. This kit form is preferred when the purpose is to provide a composition that should not be provided in a mixed state for reasons of stability, etc., but is preferably mixed and used immediately before use. Such a kit is advantageously provided with instructions or instructions describing how to use the parts provided or how to handle the reagents. When the kit is used as a reagent kit in this specification, the kit usually includes instructions describing how to use each element to constitute the nucleic acid construct.

[0040] The term "about" refers to the indicated value plus or minus 10%. When "about" is used in reference to temperature, it refers to the indicated temperature plus or minus 5° C., and when "about" is used in reference to pH, it refers to the indicated pH plus or minus 0.5.

[0041] (Preferred embodiment) Preferred embodiments of the present disclosure are described below. The embodiments provided below are provided for a better understanding of the present disclosure, and it is understood that the scope of the present disclosure should not be limited to the following description. Therefore, it is clear that a person skilled in the art can make appropriate modifications within the scope of the present disclosure in light of the description in this specification. It is also understood that the following embodiments can be used alone or in combination.

[0042] In one aspect, the present disclosure provides a nucleic acid construct for carrying out genome editing in Nannochloropsis microalgae.Any means for achieving this are contemplated within the scope of the present disclosure.For example, even if not explicitly stated, the description of a nucleic acid construct also contemplates the embodiment that reflects other means, such as the composition that comprises the nucleic acid construct, the method that uses the nucleic acid construct, and the method or material for making the nucleic acid construct.

[0043] (Nucleic acid constructs for genome editing of Nannochloropsis microalgae) In one aspect, the present disclosure provides a nucleic acid construct for performing genome editing in Nannochloropsis microalgae. Nannochloropsis microalgae have small (about 1.5 to 5 micrometers) and spherical cell bodies and are not motile. Nannochloropsis microalgae are known to be characterized by having chlorophyll a but lacking chlorophyll b and chlorophyll c. Nannochloropsis microalgae are also known to have pigments such as astaxanthin, zeaxanthin, and canthaxanthin. Nannochloropsis microalgae are known to have the ability to accumulate many polyunsaturated fatty acids, and are expected to be used as feed for fish, food additives for humans, a source of biofuel, and a source for the biological production of various useful compounds. Species of Nannochloropsis microalgae include australis, gaditana, granulata, limnetica, oceanica, oculata, and salina. These species were previously classified in the genus Nannochloropsis, but recent studies have classified some species in the genus Microchloropsis (MARVIN W. FAWLEY et al., Phycologia Volume 54 (5), 545-552). In addition, there are cases where microalgae previously classified as Marine Chlorella have been reclassified to N. oceanica. Microalgae classified into the genus Nannochloropsis or Microchloropsis according to the latest classification can be used as suitable Nannochloropsis microalgae in the present disclosure. In a specific embodiment, the nucleic acid construct of the present disclosure can be used for genome editing of Nannochloropsis microalgae of N. oceanica, N. oculata, N. gaditana (Microchloropsis gaditana), or N. granulata.

[0044] In one embodiment, the nucleic acid construct comprises a promoter sequence that recruits the Type III RNA polymerase of Nannochloropsis microalgae. In one embodiment, the nucleic acid construct comprises a sequence that encodes a guide RNA (gRNA) operably linked to the promoter sequence. In one embodiment, the nucleic acid construct comprises a terminator sequence that terminates transcription by the Type III RNA polymerase of Nannochloropsis microalgae operably linked to the sequence that encodes the gRNA. In one embodiment, the nucleic acid construct comprises these promoter sequence, gRNA encoding sequence, and terminator sequence. In one embodiment, the nucleic acid construct of the present disclosure causes genome editing in microalgae by the Crispr / Cas9 system. In one embodiment, the nucleic acid construct is a plasmid.

[0045] (Promoter) In one embodiment, the nucleic acid construct of the present disclosure includes a promoter sequence that recruits Type III RNA polymerase of Nannochloropsis microalgae to express a guide RNA. Since Type III RNA polymerase is believed not to add additional structures such as 5'-end modification and 3'-end modification to the transcript, gRNA produced by transcription with Type III RNA polymerase may enable highly efficient genome editing without activity reduction due to the addition of modified structures. The inventors have found a promoter sequence in Nannochloropsis microalgae that is expected to recruit Type III RNA polymerase, and have made highly efficient genome editing possible by utilizing this promoter sequence. Whether a nucleic acid having a specific sequence recruits Type III RNA polymerase can be examined, for example, by contacting the nucleic acid with Type III RNA polymerase derived from Nannochloropsis microalgae in vivo or in vitro and observing binding.

[0046] In one embodiment, the promoter sequence that recruits the Type III RNA polymerase of Nannochloropsis microalgae can include the promoter sequence of the U6 RNA gene of Nannochloropsis microalgae. In one embodiment, the promoter sequence can include the sequence of SEQ ID NO:1. [ka] , a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity with the sequence of SEQ ID NO: 8 or 9. In the examples of the present application, it was confirmed that genome editing can be achieved even if the underlined 24 bases of the sequence of SEQ ID NO: 1 are removed. Therefore, in one embodiment, the promoter sequence may include a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity with a sequence shortened by 1 to 50 bases (e.g., about 1, about 2, about 5, about 10, about 15, about 20, about 25, about 30, about 35, about 40, about 45, or about 50 bases, etc.) from the 3' end of the sequence of SEQ ID NO: 1.

[0047] In one embodiment, the promoter sequence is a U6 RNA-like gene sequence of SEQ ID NO: 4, which is located immediately following the sequence of SEQ ID NO: 1 at the 3' end in N. oceanica. [ka] The sequence of SEQ ID NO: 1 may further include a sequence of 1 to 10 bases (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 bases) from the 5' end. The sequence of SEQ ID NO: 1 is a sequence obtained from N. oceanica, but may also be applied to other species of Nannochloropsis microalgae. In particular, since N. oceanica is closely related to N. granulata and N. oculata (PLoS Genet. 2014 Jan;10(1):e1004094), it may be advantageously used in these species. In addition, with reference to the description in this specification, the U6 promoter sequence of Nannochloropsis microalgae other than N. oceanica can also be determined by a person skilled in the art based on the homology with the U6 RNA-like gene sequence and / or U6 promoter sequence of N. oceanica of known organisms such as mice or described herein, and can be used in the genome editing of the present disclosure in the same way as the U6 promoter sequence of N. oceanica.

[0048] (Guide RNA) In one embodiment, the nucleic acid construct of the present disclosure may include a sequence encoding a guide RNA. As used herein, the term "guide RNA" (gRNA) refers to an RNA molecule that is used in cleaving a target gene by a Cas9 protein in a CRISPR / Cas9 system, and includes a portion that targets the target gene and a portion that assists in cleaving a nucleic acid by the Cas9 protein. The guide RNA may include a CRISPR RNA (crRNA). In one embodiment, the guide RNA may not include a trans-activating CRISPR RNA (tracrRNA), and in such an embodiment, the tracrRNA may be supplied by some means in a target cell for genome editing. For example, the tracrRNA may be encoded in a portion other than the portion encoding the guide RNA on the nucleic acid construct of the present disclosure, or may be supplied by introducing a nucleic acid construct other than the nucleic acid construct of the present disclosure (e.g., a plasmid encoding tracrRNA, tracrRNA itself, etc.) into the target cell, or may be supplied endogenously in a target cell modified to express tracrRNA. In one embodiment, the guide RNA may be a single-stranded guide RNA that induces nucleic acid cleavage by the Cas9 protein as a single molecule; in this embodiment, provision of a tracrRNA may not be necessary.

[0049] In one embodiment, the guide RNA may include a portion having a sequence (which may be referred to as a homing sequence herein) that hybridizes with a portion of the target gene (e.g., a continuous base sequence having a length of about 10 to 30 bases, e.g., about 10, about 12, about 14, about 16, about 18, about 20, about 22, about 24, about 26, about 28, or about 30 bases). In the present specification, the target gene refers to a gene to be cut in the genome editing described herein, and when the gene is on a double strand, even if the portion that exerts its function (e.g., a coding sequence) is only on one of the strands, it refers to both the portion that exerts its function and the complementary portion present on the other strand. In one embodiment, the homing sequence in the guide RNA may have a sequence that is completely complementary to a portion of the target gene, but even if it does not have a sequence that is completely complementary to a portion of the target gene, it can exert a desired function as long as it can hybridize with a portion of the target gene. In one embodiment, the homing sequence in the guide RNA has a sequence that hybridizes under stringent conditions with a nucleic acid molecule having a base sequence of a portion of the target gene. In one embodiment, the homing sequence in the guide RNA may include a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity with a base sequence complementary to a portion of the target gene.

[0050] In one embodiment, the portion of the target gene targeted by the guide RNA can be determined by considering the protospacer adjacent motif (PAM). The PAM differs depending on the Cas9 protein used. For example, the Cas9 protein of S. pyogenes is known to recognize the PAM of the base sequence NGG and to cause cleavage in the target sequence adjacent to the 5' side of the PAM.

[0051] In a preferred embodiment, the homing sequence is located at the 5' end of the guide RNA. In one embodiment, the 5' end of the homing sequence is located within 1, 2, 3, 4, or 5 bases from the 5' end of the guide RNA. A partial sequence other than the homing sequence of the guide RNA can use a common sequence (for example, depending on the Cas9 protein used), and such a sequence is known to those skilled in the art or can be easily designed.

[0052] Examples of target genes include genes encoding or regulating proteins (e.g., lipid metabolism-related enzymes, photosynthesis-related genes, growth-related genes, proteins that regulate protein expression), genes encoding or regulating functional RNAs (e.g., microRNAs), and marker genes for evaluating the occurrence of genome editing (e.g., genes encoding luminescent proteins such as green fluorescent protein (GFP)). More specific examples of target genes include, for example, acetyl-CoA carboxylase gene, ADP-glucose pyrophosphorylase gene, ribulose 1,5-bisphosphate carboxylase / oxygenase gene, Lhc gene, carbonic anhydrase gene, cyclin gene, and MAP kinase gene. By appropriately selecting the target gene, modifications of the growth ability, metabolites, photosynthetic efficiency, and the like of Nannochloropsis microalgae can be achieved. Those skilled in the art can appropriately design a homing sequence that targets a suitable site of the target gene, taking into account the Cas9 protein, PAM, and the like to be used.

[0053] Those skilled in the art can design a sequence encoding a guide RNA based on the structure of the guide RNA of interest, and can prepare a nucleic acid construct containing a sequence encoding a guide RNA. The guide RNA may be complementary to a partial sequence and / or a protospacer adjacent motif (PAM) of a target gene, so that the sequence encoding the guide RNA may have a partial sequence and / or a PAM of a target gene. In one embodiment, the sequence encoding the gRNA may include the PAM of the sequence encoding the target gene and a 15-25 base sequence present on the 5' side of the PAM. In one embodiment, the sequence encoding the guide RNA may be operably linked to a promoter sequence downstream of the promoter. In one embodiment, the sequence encoding the guide RNA may be a sequence of SEQ ID NO: 3. [ka] The sequence may include a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to

[0054] (terminator) In one embodiment, the nucleic acid construct of the present disclosure comprises a terminator sequence that terminates transcription by Type III RNA polymerase of Nannochloropsis microalgae, operably linked to a sequence encoding a gRNA. For example, whether or not a terminator sequence terminates transcription by Type III RNA polymerase can be easily confirmed by a person skilled in the art, for example, by determining the length (size) of a transcript of a sequence operably linked to a promoter sequence that recruits Type III RNA polymerase as described herein. In one embodiment, the terminator sequence can include at least 3, 4, 5, 6, 7, or 8 consecutive thymine bases. In one embodiment, the terminator sequence is the sequence of SEQ ID NO:2. [ka] The sequence may include a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to

[0055] (Other elements) In one embodiment, the nucleic acid construct of the present disclosure may include a sequence encoding Cas9. In this embodiment, it may be possible to express the Cas9 protein and the guide RNA in the target cell by simply introducing a single nucleic acid construct (e.g., a plasmid), which may simplify the operation and improve the genome editing efficiency. In another embodiment, the Cas9 protein may be introduced into the target cell separately from the nucleic acid construct of the present disclosure (e.g., by transforming the target cell with another plasmid encoding the Cas9 protein, modifying the target cell to endogenously express the Cas9 protein, or by introducing the Cas9 protein into the target cell). In one embodiment, the nucleic acid construct of the present disclosure may include a sequence encoding Cas9 and a promoter sequence upstream thereof, which may be the same as or different from the promoter sequence operably linked to the guide RNA. In one embodiment, the promoter sequence upstream of the sequence encoding Cas9 may be a promoter of a constitutively expressed gene, such as the promoter of the tubulin gene of the Nannochloropsis microalgae, and such promoters can be readily determined by one of skill in the art.

[0056] The Cas9 protein used in the present disclosure may be any known Cas9 protein, and may be not only a Cas9 protein naturally obtained from a microorganism, but also a modified version thereof. Such modified versions are known to those skilled in the art, and include, for example, Cas9 proteins modified to have a nuclear localization signal. Cas9 may be from any known biological species. The sequence of the PAM recognized by Cas9 and the cleavage mode of the target nucleic acid by Cas9 are known, and a person skilled in the art can select an appropriate Cas9 according to the purpose. For example, Cas9 of S. pyogenes recognizes the PAM sequence 5'-XGG-3', Cas9 of Neisseria meningitidis recognizes the PAM sequence 5'-XXXXGATT-3', Cas9 of Streptococcus thermophilus recognizes the PAM sequence 5'-XXAGAA-3', and Cas9 of Treponema denticola recognizes the PAM sequence 5'-XAAAAC-3'. A person skilled in the art can select an appropriate Cas9 protein taking into consideration the target gene, etc.

[0057] In one embodiment, the nucleic acid construct of the present disclosure may contain a sequence encoding one or more drug selection markers. The drug selection marker may confer resistance to any drug (such as zeocin, hygromycin, etc.) that inhibits colony formation (growth) of Nannochloropsis microalgae, so that successfully transformed colonies can be formed by culturing cells transformed with a nucleic acid construct containing the drug selection marker in the presence of the drug.

[0058] In one embodiment, the nucleic acid construct (e.g., a plasmid) of the present disclosure may have a replication origin that operates in Nannochloropsis microalgae. In one embodiment, the nucleic acid construct (e.g., a plasmid) of the present disclosure may have an enhancer that operates in Nannochloropsis microalgae. Any known replication origin and / or enhancer may be used. The nucleic acid element that operates in Nannochloropsis microalgae does not need to be derived from Nannochloropsis microalgae. The nucleic acid construct of the present disclosure may be produced in cells of organisms other than Nannochloropsis microalgae, and may therefore include a replication origin, a promoter, a transcription termination sequence, and other transcriptional / translational regulatory sequences that operate in those organisms. Transcriptional / translational regulatory sequences for each organism are known and can be appropriately selected by those skilled in the art.

[0059] In certain embodiments, the present disclosure provides a nucleic acid construct comprising a sequence having at least 70%, 75%, 80%, 85%, 90%, 95%, or 99% identity to the sequence of pNAN1001 (Accession Number: NITE AP-03261), pNAN1002 (Accession Number: NITE AP-03262) or pNAN1003 (Accession Number: NITE AP-03263).

[0060] (Note) As described above, the nucleic acid construct (e.g., a plasmid) of the present disclosure, which is a preferred embodiment of the present disclosure, may have a replication origin that operates in Nannochloropsis microalgae. In one embodiment, the nucleic acid construct (e.g., a plasmid) of the present disclosure may have an enhancer that operates in Nannochloropsis microalgae. Any known replication origin and / or enhancer may be used. The nucleic acid element that operates in Nannochloropsis microalgae does not need to be derived from Nannochloropsis microalgae. The nucleic acid construct of the present disclosure may be produced in cells of organisms other than Nannochloropsis microalgae, and may therefore include a replication origin, a promoter, a transcription termination sequence, and other transcriptional / translational regulatory sequences that operate in those organisms. The transcriptional / translational regulatory sequences for each organism are known and can be appropriately selected by those skilled in the art.

[0061] (Preparation of Nucleic Acid Constructs) In one aspect, the present disclosure provides a method for producing the nucleic acid construct of the present disclosure and a nucleic acid for producing the same. The nucleic acid construct of the present disclosure can be produced by combining any suitable method (such as ligation using a restriction enzyme) that includes any element of the nucleic acid construct of the present disclosure (e.g., a promoter sequence, a sequence encoding a gRNA, a terminator sequence) alone or collectively. In one embodiment, the nucleic acid for producing the nucleic acid construct of the present disclosure can be provided as a kit. In one embodiment, the kit can include one or more containers filled with at least one of the nucleic acids for producing the nucleic acid construct of the present disclosure. The kit may include instructions showing the method for producing the nucleic acid construct. Since a common system can be used regardless of the target gene of genome editing other than the homing sequence of the guide RNA, in one embodiment, the kit can include a nucleic acid that includes the nucleic acid construct of the present disclosure alone or collectively other than the base sequence encoding the homing sequence.

[0062] (Introduction of Nucleic Acid Construct) The method of introducing the nucleic acid construct of the present disclosure into a target cell may be any method, including, for example, the use of competent target cells, electroporation, a method using a particle gun (gene gun), calcium phosphate method, and the like. Details of each method are known, and those skilled in the art can carry out the methods appropriately. The nucleic acid construct may be introduced into a target cell in the form of a circular plasmid, or may be introduced into a target cell in a linearized state by restriction enzyme treatment or PCR. In addition, only a portion containing a necessary element among the elements constituting the nucleic acid construct may be extracted by restriction enzyme treatment or PCR, and then introduced into the target cell. It is contemplated that the nucleic acid construct of the present disclosure includes both a nucleic acid construct to be introduced into a target cell and a nucleic acid construct (e.g., a plasmid) that is the source for preparing the nucleic acid construct to be introduced into the target cell. In one embodiment, the present disclosure provides a cell (such as Nannochloropsis microalgae) transformed with the nucleic acid construct of the present disclosure. Whether or not a cell has been transformed can be confirmed by any marker (such as expression of a color-producing protein, drug resistance, etc.).

[0063] (composition) In one embodiment, the present disclosure provides a composition for performing genome editing, comprising the nucleic acid construct of the present disclosure. The composition can be provided in any suitable form (e.g., a fluid containing the nucleic acid construct). The composition can include any suitable component, such as a component for stabilizing the nucleic acid construct of the present disclosure, a component that does not damage target cells, etc.

[0064] In this specification, "or" is used when "at least one or more" of the items listed in the sentence can be employed. The same applies to "alternative." In this specification, when "within the range of" two values ​​is specified, the range includes the two values ​​themselves.

[0065] All references cited herein, including scientific literature, patents, patent applications, and the like, are hereby incorporated by reference in their entirety to the same extent as if each was specifically set forth. EXAMPLES

[0066] The specific reagents used were those described in the Examples, but equivalent products from other manufacturers (Sigma-Aldrich, Wako Pure Chemical Industries, Nakarai, R&D Systems, USCN Life Science INC, etc.) can also be used.

[0067] (Construction of a plasmid for expressing cas9 in Nannochloropsis microalgae) In order to stably express cas9 in Nannochloropsis microalgae, we first constructed a plasmid pNAN0002 expressing the Zeocin resistance gene using the β-tubulin promoter of Nannochloropsis oceanica NIES 2145 strain (obtained from the National Institute for Environmental Studies) and the Nos terminator derived from pCAMBIA1300, and then introduced a cassette expressing the Cas9 gene with the α-tubulin gene promoter of N. oceanica NIES 2145 strain into pNAN0002 to obtain pNAN0006. The outline of the plasmid is shown in Figure 2.

[0068] pNAN0002 was constructed as follows. The downstream of the Zeocin resistance gene of pEM7 / Zeo (Invitrogen, V50020) was cleaved by PCR using primers P1 and P2, and the DNA fragment of the Nos terminator of about 300 bp obtained by PCR using primers P3 and P4 from pCAMBIA1300 (purchased from Marker Gene Technologies, Inc., USA) was connected by in-fusion method to obtain pEM7 / Zeo-NosT. Next, the sequence coding for β-tubulin was searched for in the database of N. oceanica CCMP1779 v2.0 on the JOINT GENOME INSTITUTE website (https: / / jgi.doe.gov / ), and the upstream sequence was identified as the promoter sequence. The upstream region of pEM7 / Zeo-NosT was cleaved by PCR using P5 and P6, and a DNA fragment of approximately 550 bp of the β-tubulin promoter obtained from N. oceanica NIES 2145 strain by PCR using P7 and P8 was ligated to the fragment by in-fusion method to obtain pNAN0002 of approximately 3.6 Kbp.

[0069] A cassette expressing the Cas9 gene using the α-tubulin gene promoter of the 2145 strain was constructed as follows. The sequence (below) containing the Cas9 gene and terminator sequence modified by Imad Ajjawi et al. based on SpCas9 (a portion of the sequence (2780bp-7347bp) described in Supplementary Note 1 of Nature Biotechnology VOLUME 35 NUMBER 7 2017 647-655) was totally synthesized to obtain the plasmid pNAN-cas9-t. Sequence number 5:>2780-7347 [ka] [ka] [ka]

[0070] The sequence coding for α-tubulin was searched for in the database of N. oceanica CCMP1779 v2.0 on the JOINT GENOME INSTITUTE website (https: / / jgi.doe.gov / ), and the upstream sequence was identified as the promoter sequence (SEQ ID NO: 6). A DNA fragment of the promoter region of the α-tubulin gene of approximately 1000 bp was obtained from N. oceanica NIES 2145 strain by PCR using P29 and P30, and confirmed by electrophoresis (Figure 1). SEQ ID NO: 6: α-tubulin promoter [ka]

[0071] The upstream of the Cas9 gene in pNAN-cas9-t was cleaved by PCR using primers P26 and P27, and connected to the DNA encoding the approximately 1000 bp α-tubulin promoter by in-fusion method to obtain pNAN aTubP-Cas9-t. The DNA fragment encoding the expression cassette of pNAN aTubP-Cas9-T (α-tubulin promoter: Cas9 gene: terminator) was obtained by PCR using primers P17 and P28, and pNAN0002 was ligated by blunt ligation to the fragment cleaved by PCR using primers P31 and P32 to obtain pNAN0006 (Figure 2).

[0072] pNAN0006 was introduced into N. oceanica NIES 2145 by electroporation, and colonies were selected based on Zeocin resistance to generate transformants (2, 3, and 4 each represent a different colony). The transformants were lysed, proteins were extracted, and SDS-PAGE was performed (Figure 3B). Western blotting was then performed using an anti-Cas9 antibody (Guide-it Cas9 Polyclonal Antibody, 632607, Takara Bio) to compare Cas9 protein production with that of the wild-type strain (1) (Figure 3C). Cas9 protein was not detected in the wild-type strain, but was only detected in the transformants.

[0073] (Construction of plasmids for expressing sgRNA in Nannochloropsis microalgae) The outline of the construction is shown in Figure 4. We investigated a promoter for expressing sgRNA in Nannochloropsis microalgae. We searched for Nannochloropsis genes corresponding to the promoter of the U6 gene, which is known to mobilize Type III RNA polymerase in humans and other organisms. We searched for sequences homologous to the mouse U6 gene in the N. oceanica CCMP1779 v2.0 database and identified a region containing a base sequence that may be the U6-like gene of N. oceanica. The U6-like gene region has low conservation at the site thought to be the transcription start point, and may be a pseudogene, making it particularly difficult to identify the transcription start point. We identified the region upstream of GTATAA in the N. oceanica U6-like gene (sequence number 4) as the U6 promoter (sequence number 7), and the downstream region as the terminator (sequence number 2). SEQ ID NO:4: U6-like gene [ka] SEQ ID NO: 7: U6 promoter [ka] SEQ ID NO:2: U6 terminator [ka]

[0074] Based on this, a U6 gene-like sequence and its surrounding sequences were obtained from the N. oceanica NIES 2145 strain by PCR using primers P33 and P34, and inserted into pGEM-T Easy Vector (Promega) to obtain 2145-U6-Tvec (the partial sequence is shown in Figure 5 ).

[0075] Using 2145-U6-Tvec as a template and three primer pairs (P37 and P38, P37 and P39, and P37 and P40), we performed inverse PCR to obtain a DNA fragment lacking the U6-like gene but containing the U6 terminator and three types of U6 promoter sequences of different lengths.

[0076] A fragment of sgRNA containing a sequence complementary to sGFP was inserted into these three fragments by the in-fusion method. The sgRNA containing a sequence complementary to sGFP was prepared as follows: a plasmid (pGuide-it-sGFP36-58) containing a sequence corresponding to the sgRNA was obtained using oligo DNA P35 and P36 and the Guide-it CRISPR / Cas9 System (Green) (Clontech, Cat. No. 632601).

[0077] Using pGuide-it-sGFP36-58 as a template, three sets of primer pairs (P41 and P42, P41 and P43, P41 and P44) were used to obtain three types of DNA fragments. The fragments derived from P37 and P38 were linked to the fragments derived from P41 and P42, the fragments derived from P37 and P39 were linked to the fragments derived from P41 and P43, and the fragments derived from P37 and P40 were linked to the fragments derived from P41 and P44 by in-fusion method, to obtain pU6-1 sGFP36-55, pU6-2 sGFP36-55, and pU6-3 sGFP36-55, respectively.

[0078] pU6-1 sGFP36-55, pU6-2 sGFP36-55, and pU6-3 sGFP36-55 were each digested with NotI to obtain DNA fragments encoding the U6 promoter (three types of different lengths; SEQ ID NO: 8, 9, and 1, respectively), gRNA (SEQ ID NO: 10), and U6 terminator (SEQ ID NO: 2).

[0079] The three types of U6 promoters, gRNA, and U6 terminator coding sequences described in the previous section were introduced into the NotI site of a plasmid (pNAN0006) containing a cas9 coding sequence downstream of the α-tubulin promoter to create pNAN1001, pNAN1002, and pNAN1003. SEQ ID NO: 8: U6 promoter (pNAN1001) [ka] SEQ ID NO: 9: U6 promoter (pNAN1002) [ka] Sequence number 73 :U6 promoter (pNAN1003) [ka] SEQ ID NO: 10: gRNA [ka] (The underlined part of the sequence encoding GFP (target sequence); the bolded part is the PAM of cas9.) Sequence number 2: U6 terminator [ka]

[0080] pNAN1001, pNAN1002, and pNAN1003 were deposited at the National Institute of Technology and Evaluation (NITE) Patent Microorganisms Depositary and received on August 19, 2020. The accession numbers are NITE AP-03261, NITE AP-03262, and NITE AP-03263, respectively.

[0081] (Confirmation of sgRNA expression) These plasmids were used to transform N. oceanica NIES 2145. RNA was extracted from the pNAN1001 transformant, pNAN1002 transformant, pNAN1003 transformant, and wild-type strain, and contaminating genomic DNA was digested with DNase, after which cDNA was synthesized using reverse transcriptase. The cDNA was then used as a template to detect sgRNA by PCR. The size of the target sgRNA was 110 bp. Since the 110 bp band was not detected in the sample to which reverse transcriptase was not added, it was confirmed that the 110 bp band was derived from the sgRNA transcribed in the cells (Figure 7A). In addition, the mRNA of β-tubulin, which is constitutively expressed in N. oceanica, was detected by RT-PCR using an equivalent amount of RNA to the above, and it was confirmed that the same amount of sample was used in the above experiment (Figure 7B).

[0082] (Genome editing detection) We tested whether genome editing occurred by introducing the constructed plasmid. A plasmid encoding GFP, pNAN0005, was constructed. The structure of pNAN0005 is shown in Figure 8. The T-BORDER(L) to T-BORDER(R) of pNAN0005 was extracted by PCR using P13 and P14, and this was used to transform N. oceanica NIES 2145, creating a strain that emits green fluorescence of GFP as a model experimental system (Figure 9A). A genome editing vector (pNAN1001, pNAN1002 or pNAN1003) was introduced into this GFP-expressing strain. When genome editing occurs in the GFP gene, the GFP gene becomes nonfunctional and the GFP fluorescence is lost. After the introduction of the plasmid, one of the following colonies appears: GREEN (Figure 9B), MIX (Figure 9C) or RED (Figure 9D). GREEN refers to a colony without genome editing, MIX refers to a colony in which genome editing occurred during the colony formation process, and RED refers to a colony formed from a single genome-edited cell. In addition, a RED colony can be produced by obtaining a single cell from a MIX colony. [Table 1]

[0083] All plasmids were found to be highly efficient at genome editing, with pNAN1003 being particularly efficient.

[0084] (Analysis of GFP gene in pNAN1002 transformants) A single cell was obtained from the MIX colony of the pNAN1002 transformant described above, and a RED colony was formed and analyzed (1 to 10 each indicate a different colony). Plasmid was extracted from the colony, and a nucleic acid fragment (201 bp or 756 bp) containing the GFP gene of pNAN0005 was amplified by PCR, and the amplified fragment was digested with AluI (Figure 10). The 5' portion of the amplified GFP gene contains four AluI recognition sites, as underlined below. [ka] The sgRNA produced from pNAN1002 may introduce modifications into the second AluI recognition site, resulting in the loss of the second AluI recognition site and the generation of an approximately 105 bp fragment having the base sequence between the first and third AluI recognition sites.

[0085] Samples 1, 2, 5, and 6, which amplified a 201 bp fragment, were confirmed to produce a 105 bp band upon AluI treatment, and sample 7, which amplified a 756 bp fragment, was confirmed to produce a 105 bp band upon AluI treatment. Therefore, genome editing was confirmed in these samples.

[0086] Next, the nucleotide sequence of the GFP gene was determined for the samples in which genome editing was confirmed (Figure 11). As a result, a 5 bp deletion in the GFP gene of samples 1, 2, 5, and 6, and a 1 bp substitution in the GFP gene of sample 7 were confirmed.

[0087] (Design of sgRNA for CA2 gene) An sgRNA sequence (SEQ ID NO: 13) was designed that targets a sequence in the CA2 gene (SEQ ID NO: 12) of N. oceanica. Sequence number 12: CA2 gene [ka] (The underlined portion indicates the complementary sequence of the target sequence.) SEQ ID NO: 13: 5' end sequence of sgRNA [ka] (Underlining indicates gRNA sequence, bold indicates PAM.)

[0088] A plasmid containing this sgRNA sequence was constructed based on pNAN1002. Specifically, PCR was performed using pNAN1002 as a template and primers P39 and P51. The PCR product was self-ligated to produce pNAN1006 (FIG. 12).

[0089] (Detection of genome editing in the CA2 gene) N. oceanica NIES 2145 was transformed with pNAN1006, and zeocin-resistant colonies (colonies 3 to 10) were formed by incubation in the presence of zeocin. For the wild type and each colony, PCR was performed to amplify a part of the CA2 gene (516 bp), and the PCR product was digested with EcoRV and analyzed (Figure 13). When genome editing occurs, the EcoRV recognition sequence present within the 516 bp (present in the targeted sequence in the CA2 gene) changes, and a mutant that is not cut by EcoRV appears. The presence of a 516 bp fragment was confirmed in the electrophoretic pattern, indicating that genome editing occurred in the CA2 gene.

[0090] (Genome editing using different strains) pNAN0005 is introduced into various strains of Nannochloropsis microalgae to generate strains that emit GFP fluorescence. Next, pNAN1001, 1002, or 1003 is introduced into these GFP-emitting strains. Strains that may have undergone genome editing because the GFP fluorescence disappears are selected, and finally, the base sequence of the relevant part is determined to confirm genome editing.

[0091] Specifically, we confirmed that genome editing is possible in N. oculata, N. gaditana (Microchloropsis gaditana), and N. granulata as follows.

[0092] 1. Construction of strains for genome editing monitoring To monitor genome editing in N. oculata NIES-2146, N. gaditana NIES-2587, and N. granulata NIES-2588 obtained from the National Institute for Environmental Studies, the GFP-expressing plasmid pNAN0005 was introduced into each strain by electroporation.

[0093] 2. Introduction of pNAN1002 into the strains to be monitored pNAN1002 is an all-in-one vector that performs genome editing on the GFP gene. Strains into which pNAN1002 has been introduced acquire Zeocin resistance. Furthermore, if the introduced strain contains the GFP gene, genome editing is performed on the GFP gene. In cells in which genome editing has occurred, the sequence of the GFP gene changes and GFP fluorescence is lost. Cells that have lost GFP fluorescence begin to emit chlorophyll autofluorescence (red). pNAN1002 was further introduced into the above pNAN0005-introduced strain. After that, single colony isolation was performed from colonies containing red parts that appeared on the selective medium containing Zeocin, and colonies that were red overall were obtained.

[0094] The results are shown in Figure 14. By introducing pNAN0005, each strain began to show green fluorescence (Figures 14A-C), but in colonies where genome editing was performed by further introducing pNAN1002, cells that had lost the fluorescence of the target GFP appeared, and chlorophyll autofluorescence (red) was partially observed (Figures 14D, E). Furthermore, by single colony isolation from colonies containing red parts, colonies that showed an overall red color were obtained (Figures 14F-H).

[0095] 3. Confirmation of genome editing by base sequence analysis The researchers analyzed the structural changes in the GFP gene in the cell lines that had lost their GFP fluorescence and turned red. They isolated fragments of the GFP gene from each cell line that had lost its fluorescence after genome editing by PCR, and determined the sequence of the target region by Sanger sequencing.

[0096] The results are shown in Figure 15. In all strains derived from NIES-2146 (2146-7c, 2146-8C), NIES-2587 (2587-9C, 2587-12c), and NIES-2588 (2588-3c, 2588-9c), it was observed that a mutation occurred in the base sequence at the target site (upstream of the PAM sequence (TGG)) of the GFP gene. It was shown that the nucleic acid construct of the present disclosure is capable of genome editing of various Nannochloropsis microalgae.

[0097] The primers used in this example are listed below. [Table 2-1] [Table 2-2] [Table 2-3]

[0098] (Note) Although the present disclosure has been illustrated using the preferred embodiments thereof, it is understood that the present disclosure should be interpreted in scope only by the claims. It is understood that the patents, patent applications and literature cited in this specification should be incorporated by reference in their entirety as if the contents themselves were specifically set forth in this specification. [Industrial Applicability]

[0099] The present disclosure may enable highly efficient genome editing in Nannochloropsis microalgae, and may provide advantages in various applications using Nannochloropsis microalgae (biofuel production and other bioconversion, feed, etc.). [Accession number]

[0100] pNAN1001 (Receipt number: NITE AP-03261) pNAN1002 (Receipt number: NITE AP-03262) pNAN1003 (Accession number: NITE AP-03263)

Claims

1. A promoter sequence that recruits Type III RNA polymerase from Nannochloropsis microalgae; a sequence encoding a guide RNA (gRNA) operably linked to the promoter sequence; and A terminator sequence that terminates transcription by the Type III RNA polymerase of Nannochloropsis microalgae, operably linked to the sequence encoding the gRNA; A nucleic acid construct comprising: The promoter sequence is the sequence of SEQ ID NO:1 (CCAAATGTCTTTGACGGTCGTCACGGTTTTGCGTCGTAAAACCTACGCAAGGAAAATTACCATCATCGACCCGACACAAACAAGCGGTCCTTAGAAATCAGGACCTTTTATTTTTTAAGAAGGGAGTGAATGGGTAACAT TTCGTGGTGAGACTTCAACGAAAGTTTGGAGAAAAATTCCACATGTTGTACGCTCCCGGAAAAGAGAAGGAATATAAGGGCGTCACGAGTCATGACTTTCTAAACAGCAAGGTTCGCGTGAAACTCGTTTACGGGAAACC) or a promoter sequence of the U6 RNA gene of Nannochloropsis microalgae, comprising a sequence shortened by 1 to 24 bases from the 3' end of the sequence of SEQ ID NO: 1; Nucleic acid constructs.

2. The nucleic acid construct of claim 1 , wherein the terminator sequence comprises at least 4 consecutive thymidine bases.

3. 3. The nucleic acid construct of claim 1 or 2, wherein the terminator sequence is the terminator sequence of the U6 RNA gene of Nannochloropsis microalgae.

4. The terminator sequence is the sequence of SEQ ID NO:2 (TTTTTTTTCTTTTGATCAAATTACATTCTGATTCTTAGATACTTCACATGTTGATACTCCAC) The nucleic acid construct according to any one of claims 1 to 3, comprising a sequence having at least 85% identity with

5. 5. The nucleic acid construct of claim 1, wherein the gRNA-encoding sequence comprises a protospacer adjacent motif (PAM).

6. The sequence encoding the gRNA is the sequence of SEQ ID NO: 3 (GTTTAAGAGCTATGCTGGAAACAGCATAGCAAGTTTAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGC) The nucleic acid construct according to any one of claims 1 to 5, comprising a sequence having at least 85% identity with

7. The nucleic acid construct according to any one of claims 1 to 6, wherein the sequence encoding the gRNA comprises a sequence of 15 to 25 bases in length of a sequence encoding a target gene.

8. The nucleic acid construct according to any one of claims 1 to 7, wherein the sequence encoding the gRNA comprises a PAM and a 15 to 25 base sequence located on the 5' side of the PAM in the sequence encoding the target gene.

9. The nucleic acid construct of claim 7 or 8, wherein the target gene is green fluorescent protein (GFP).

10. The nucleic acid construct of any one of claims 1 to 9, wherein the gRNA is a single-stranded guide RNA.

11. The nucleic acid construct of any one of claims 1 to 10, further comprising a sequence encoding a Cas9 protein.

12. The nucleic acid construct according to any one of claims 1 to 11, further comprising a sequence encoding a drug selection marker.

13. The nucleic acid construct according to any one of claims 1 to 12, wherein the Nannochloropsis microalgae is Nannochloropsis oceanica.

14. The nucleic acid construct according to any one of claims 1 to 13, which is a plasmid.

15. A Nannochloropsis microalga comprising the nucleic acid construct according to any one of claims 1 to 14.

16. A kit for preparing a nucleic acid construct for performing genome editing in Nannochloropsis microalgae, A nucleic acid comprising a promoter sequence that recruits the Type III RNA polymerase of the Nannochloropsis microalga, said promoter sequence being the sequence of SEQ ID NO:

1. (CCAAATGTCTTTGACGGTCGTCACGGTTTTGCGTCGTAAAACCTACGCAAGGAAAATTACCATCATCGACCCGACACAAACAAGCGGTCCTTAGAAATCAGGACCTTTTATTTTTTAAGAAGGGAGTGAATGGGTAACAT TTCGTGGTGAGACTTCAACGAAAGTTTGGAGAAAAATTCCACATGTTGTACGCTCCCGGAAAAGAGAAGGAATATAAGGGCGTCACGAGTCATGACTTTCTAAACAGCAAGGTTCGCGTGAAACTCGTTTACGGGAAACC) or a nucleic acid comprising a sequence shortened by 1 to 24 bases from the 3' end of the sequence of SEQ ID NO: 1; A nucleic acid containing a terminator sequence that terminates transcription by Type III RNA polymerase of Nannochloropsis microalgae. Including the kit.

17. 1. A method for performing genome editing in Nannochloropsis microalgae, comprising: A step of introducing the nucleic acid construct according to any one of claims 1 to 14 or the nucleic acid in the kit according to claim 16 into Nannochloropsis microalgae. The method includes:

Citation Information

Patent Citations

  • Compositions and Methods for High-Efficiency In Vivo Genome Editing

    JP2018500037A

  • Method for producing microalgae with thinned cell wall by controlling expression of polysaccharide lyase or cellulose synthase

    KR1020200038860A

  • Methods for non-transgenic genome editing in plants

    WO2014199358A1